ReviewFrontiers in pharmacology2026
Polyphenol-based modulation of the Glo1-Nrf2-RAGE axis in diabetes and neurodegeneration: mechanistic evidence, translational constraints, and critical appraisal.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The key pathological mechanisms in diabetes and neurodegeneration generally involve a progressive accumulation of reactive carbonyl species (RCS), accompanied by increased oxidative stress and the accumulation of inflammatory mediators. Thus, a clear understanding of the Glo1-Nrf2-RAGE axis is crucial as it plays a key role in redox imbalance, regulation of cell responses to methylglyoxal (MG)-induced glycation, and chronic inflammation. Even though glyoxalase I (Glo1) detoxifies MG to mitigate advanced glycation end product (AGE) formation, the transcription of antioxidant enzymes by nuclear factor erythroid 2-related factor 2 (Nrf2) is reactivated. Conversely, persistent activation of the receptor for AGE (RAGE) further amplifies inflammatory cascades and tissue damage. A continuous dysregulation of "this axis" can contribute to the pathogenesis of several complications, including diabetes and neurodegeneration. Nevertheless, polyphenols have emerged as nutraceutical candidates that may modulate the Glo1-Nrf2-RAGE axis due to their specialized structural features. Key polyphenols, such as quercetin, resveratrol, curcumin, epigallocatechin gallate, luteolin, and apigenin, enhance Glo1 expression and activity, promote Nrf2 nuclear translocation via Keap1 modification, and lower RAGE expression and ligand binding. However, numerous challenges, such as limited bioavailability, metabolic instability, and "interindividual variability," hinder their clinical translation. We have tried to fill the research gap by combining recent evidence from preclinical, clinical, and molecular studies, with the aim of highlighting the pleiotropic effects of these metabolites. In addition, the molecular effects of polyphenolics with reference to modulation of mitochondrial function, regulation of epigenetic mechanisms, and interactions with the gut-brain axis are detailed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.